REG - C4X Discovery - Bhavna Hunjan Appointed as Chief Business Officer

C4X Discovery HoldingsAnnouncement

01/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220201:nRSA2216Aa&default-theme=true

RNS Number : 2216A  C4X Discovery Holdings PLC  01 February 2022

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Bhavna Hunjan Appointed to the Board as Chief Business Officer

 

1 February 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces the appointment of Bhavna Hunjan to the
Board of Directors, as Chief Business Officer, with immediate effect.

 

Bhavna joined C4XD in 2016 and, since becoming Head of Corporate Strategy and
Development in 2017, has played a critical role in a series of successful
licensing deals and strategic partnerships, as well as driving business growth
and capital raising as part of the Executive Management team.  In her new
role, Bhavna will be responsible for shaping the strategic direction of C4XD.
 She will lead corporate development activities including developing and
executing C4XD's deal strategy to build shareholder value, intelligence-driven
strategic planning, commercial evaluation of new projects and alliances, and
she will represent C4XD in external activities including investor relations,
fundraising, M&A, and external communications.

 

Bhavna was named a Rising Star in the Movers & Shakers in BioBusiness 2017
and voted one of the 30 Rising Leaders in Life Sciences 2020 by In Vivo.
 Previously, Bhavna spent 15 years in commercial and corporate roles at
Lehman Brothers, Nomura International, PwC and Cancer Research UK.  She holds
a first-class Masters degree in Biochemistry from the University of Oxford.

 

In addition, Emma Blaney has been promoted to Chief Operating Officer.  Emma
joined C4XD in 2014 as a Senior Programme Manager and became VP Operations in
2016.  In her new role, Emma will oversee operations, governance and policies
as well as portfolio management, employee productivity and building on the
Company's highly inclusive culture.  Emma has a PhD in Synthetic Organic
Chemistry from the University of Leeds, and a first-class Chemistry and
Pharmacology degree from the University of Liverpool.

 

Eva-Lotta Allan, Chairman of C4X Discovery, commented: "I am delighted to
announce these two key appointments today.  Bhavna has been instrumental in
steering the Company over the past six years to where we are today.  Her
business acumen, married with her ability to drive deals to commercial success
and understanding of how the markets operate, has helped to build C4XD into a
strong, commercial Drug Discovery company.  Bhavna joining the Board is a
natural step and reflects the key role she plays within the management team; I
look forward to working with her in the coming years.

 

"Furthermore, promoting Emma to COO was an easy choice. Emma first joined C4XD
as a chemist and has grown into an incredible Operations Manager, keeping a
steady ship at all times and running the business on a day-to-day basis with
the utmost attention to detail and care.  The positive impact Emma and Bhavna
have had on the business overall has been fundamental to the success of the
Company."

 

Additional Disclosures

Bhavna Hunjan (aged 36) holds options over 655,556 ordinary shares in the
Company which have been granted to her during the course of her employment.

There is no further information regarding Bhavna Hunjan required to be
disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM
Rules for Companies, other than those disclosed above.

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKDBPOBKDCDN